CD8A and neoplasm: Despite the variable mutational load across different human malignancies (19) and the technical challenges, tumor-infiltrating, as well as circulating, neoantigen-specific CD8+ and CD4+ T-cells have now been identified and characterized in several tumor types (20–25).